Opus Genetics (IRD) Free Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
Opus Genetics (IRD) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -1.95% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -20.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 21.16% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 45.09% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 80.69% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -4.45% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 8.92% |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | -141.49% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -141.49% |
| Mar 31, 2026 | -51.69% |
| Dec 31, 2025 | -32.79% |
| Sep 30, 2025 | -11.03% |
| Jun 30, 2025 | -39.18% |
| Mar 31, 2025 | -13.39% |
| Dec 31, 2024 | -9.62% |
| Sep 30, 2024 | -12.70% |
| Jun 30, 2024 | -18.99% |
| Mar 31, 2024 | 0.55% |
| Dec 31, 2023 | 44.92% |
| Sep 30, 2023 | -41.68% |
| Jun 30, 2023 | 52.11% |
| Mar 31, 2023 | -70.78% |
| Dec 31, 2022 | 79.65% |
| Sep 30, 2022 | -23.67% |
| Jun 30, 2022 | -28.08% |
| Mar 31, 2022 | -11.99% |
| Dec 31, 2021 | -6.91% |
| Sep 30, 2021 | 5.17% |